Beam Therapeutics Inc. EV/FCF

EV/FCF of BEAM for past 10 years: annual, quarterly and twelve month trailing (TTM) including EV/FCF growth rates and interactive chart. A valuation metric that measures the enterprise value of a stock compared to its free cash flow. Free cash flow is calculated as operating cash flow - capital expenditures and is a more accurate measure of a company's earning power than net income, as it's not easily manipulated. A low EV/FCF ratio can indicate undervaluation, while a high one might mean the growth expectations around the company are elevated. EV/FCF ratio can be compared to different companies in the same industry or to a company’s own historical valuation.

Highlights and Quick Summary

Current EV/FCF of Beam Therapeutics Inc. is -36.69 (as of December 31, 2021)
  • EV/FCF for the quarter ending September 30, 2022 was 96.71 (a 495.56% increase compared to previous quarter)
  • Year-over-year quarterly EV/FCF decreased by -363.61%
  • Annual EV/FCF for 2021 was -36.69 (a 13.53% increase from previous year)
  • Annual EV/FCF for 2020 was -32.32 (a 4386.55% increase from previous year)
Visit stockrow.com/BEAM for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical EV/FCF of Beam Therapeutics Inc.

Most recent EV/FCFof BEAM including historical data for past 10 years.

Interactive Chart of EV/FCF of Beam Therapeutics Inc.

Beam Therapeutics Inc. EV/FCF for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 – 96.71 16.24 19.64 –
2021 -36.69 -36.33 -48.54 -33.81 -36.69
2020 -32.32 -10.69 -12.68 -3.87 -32.32
2019 -0.72 -0.72 -0.72 – -0.72

Business Profile of Beam Therapeutics Inc.

Sector: Healthcare
Industry: Biotechnology
© stockrow.com